231. α1−アンチトリプシン欠乏症 Alpha-1-antitrypsin deficiency Clinical trials / Disease details

臨床試験数 : 93 / 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36

45 trials found

diseases per page:

Showing 1 to 10 of 45 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05579431 (ClinicalTrials.gov)	October 13, 2022	10/10/2022	A Phase 1, First-in-human Study of VX-634	A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-634	Alpha 1-Antitrypsin Deficiency	Drug: VX-634;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Recruiting	18 Years	55 Years	All	114	Phase 1	United States
2	NCT04764448 (ClinicalTrials.gov)	February 12, 2021	27/1/2021	A Study of Belcesiran in Patients With AATLD	A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Ph ...	Alpha 1-Antitrypsin Deficiency	Drug: Belcesiran;Other: Placebo	Dicerna Pharmaceuticals, Inc.	NULL	Recruiting	18 Years	75 Years	All	46	Phase 2	Australia;Austria;Belgium;Canada;France;Germany;Ireland;Netherlands;New Zealand;Portugal;Spain;Swede ...
3	EUCTR2019-000602-30-SE (EUCTR)	29/06/2020	24/04/2020	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficac ...	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficac ...	Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limit ...	Product Name: Kamada -AAT for Inhalation or inhaled AAT (AAT) INN or Proposed INN: Alpha-1 Antitrypsi ...	Kamada Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Argentina;Finland;Belgium;Ireland;Netherlands;United Kingdom;Italy;Sweden
4	NCT04167345 (ClinicalTrials.gov)	January 13, 2020	15/11/2019	Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 i ...	Alpha 1-Antitrypsin Deficiency	Drug: VX-814;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Terminated	18 Years	80 Years	All	48	Phase 2	United States;Canada;Germany;Ireland
5	NCT03946449 (ClinicalTrials.gov)	December 19, 2019	8/5/2019	Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)	A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patien ...	Alpha 1-Antitrypsin Deficiency	Drug: ARO-AAT Injection	Arrowhead Pharmaceuticals	NULL	Active, not recruiting	18 Years	75 Years	All	16	Phase 2	Austria;Germany;United Kingdom
6	NCT04174118 (ClinicalTrials.gov)	October 24, 2019	6/11/2019	Study of DCR-A1AT in Healthy Adult Volunteers	A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study ...	Alpha 1-Antitrypsin Deficiency	Drug: belcesiran;Drug: Placebo	Dicerna Pharmaceuticals, Inc.	NULL	Active, not recruiting	18 Years	55 Years	All	30	Phase 1	New Zealand;Sweden
7	EUCTR2019-000602-30-NL (EUCTR)	30/09/2019	15/05/2019	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficac ...	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficac ...	Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limit ...	Product Name: Kamada -AAT for Inhalation or inhaled AAT (AAT) INN or Proposed INN: Alpha-1 Antitrypsi ...	Kamada Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Finland;Belgium;Ireland;Netherlands;United Kingdom;Sweden
8	NCT03945292 (ClinicalTrials.gov)	August 7, 2019	8/5/2019	Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)	A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacody ...	Alpha 1-Antitrypsin Deficiency	Drug: Fazisiran Injection;Other: Placebo	Arrowhead Pharmaceuticals	NULL	Active, not recruiting	18 Years	75 Years	All	40	Phase 2	United States;Germany;Italy;Netherlands;Portugal;Spain;Canada;Ireland;Sweden
9	NCT03636347 (ClinicalTrials.gov)	October 29, 2018	20/6/2018	A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH9 ...	A Phase 2, Proof-of-concept, Multicentre, Double-blind, Randomised, Dose-ascending, Sequential Group ...	Alpha 1-Antitrypsin Deficiency;Emphysema;COPD	Drug: Placebo Oral Tablet;Drug: Alvelestat oral tablet - dose 1;Drug: Alvelestat oral tablet - dose 2	Mereo BioPharma	Syneos Health	Completed	18 Years	75 Years	All	99	Phase 2	United States;Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom
10	NCT03385395 (ClinicalTrials.gov)	July 2018	1/12/2017	Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® ...	A Randomized, Double-blind, Parallel-group, Multicenter, Pharmacokinetic Study Comparing Weekly Intr ...	Alpha 1-Antitrypsin Deficiency	Drug: OctaAlpha1;Drug: Glassia	Octapharma	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	NULL

First Previous1 2 3 4 5Next Last